ZÁVACKÁ, Kristýna and Karla PLEVOVÁ. Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability. Online. Frontiers in Oncology. Lausanne: Frontiers Media S.A., 2021, vol. 11, November 2021, p. 1-9. ISSN 2234-943X. Available from: https://dx.doi.org/10.3389/fonc.2021.771664. [citováno 2024-04-23]
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability
Authors ZÁVACKÁ, Kristýna (203 Czech Republic, belonging to the institution) and Karla PLEVOVÁ (203 Czech Republic, guarantor, belonging to the institution)
Edition Frontiers in Oncology, Lausanne, Frontiers Media S.A. 2021, 2234-943X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.738
RIV identification code RIV/00216224:14110/21:00120226
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3389/fonc.2021.771664
UT WoS 000729014900001
Keywords in English chromothripsis; chronic lymphocytic leukemia; complex chromosomal rearrangements; copy number alterations; genomic array; paired-end sequencing; oncogene amplification; tumor suppressor inactivation
Tags 14110212, 14110323, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 8/2/2022 14:03.
Abstract
Chromothripsis represents a mechanism of massive chromosome shattering and reassembly leading to the formation of derivative chromosomes with abnormal functions and expression. It has been observed in many cancer types, importantly, including chronic lymphocytic leukemia (CLL). Due to the associated chromosomal rearrangements, it has a significant impact on the pathophysiology of the disease. Recent studies have suggested that chromothripsis may be more common than initially inferred, especially in CLL cases with adverse clinical outcome. Here, we review the main features of chromothripsis, the challenges of its assessment, and the potential benefit of its detection. We summarize recent findings of chromothripsis occurrence across hematological malignancies and address its causes and consequences in the context of CLL clinical features, as well as chromothripsis-related molecular abnormalities described in published CLL studies. Furthermore, we discuss the use of the current knowledge about genome functions associated with chromothripsis in the optimization of treatment strategies in CLL.
Links
EF16_026/0008448, research and development projectName: Analýza českých genomů pro teranostiku
MUNI/A/1595/2020, interní kód MUName: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VIII (Acronym: VýDiTeHeMa VIII)
Investor: Masaryk University
MUNI/IGA/1640/2020, interní kód MUName: Exploring clonal evolution and causes of modern targeted therapy failure in CLL
Investor: Masaryk University
NU21-08-00237, research and development projectName: Pokročilé sekvenační metody pro analýzu strukturních přestaveb nádorového genomu
Investor: Ministry of Health of the CR, Advanced sequencing methods for deciphering structural variants in cancer genome, Subprogram 1 - standard
PrintDisplayed: 23/4/2024 12:11